Volume 13, Number 2—February 2007
Meningococcal Disease in South Africa, 1999–2002
We describe the epidemiology of invasive meningococcal disease in South Africa from August 1999 through July 2002, as reported to a laboratory-based surveillance system. Neisseria meningitidis isolates were further characterized. In total, 854 cases of laboratory-confirmed disease were reported, with an annual incidence rate of 0.64/100,000 population. Incidence was highest in infants <1 year of age. Serogroup B caused 41% of cases; serogroup A, 23%; serogroup Y, 21%; serogroup C, 8%; and serogroup W135, 5%. Serogroup B was the predominant serogroup in Western Cape Province, and disease rates remained stable. Serogroup A was most prevalent in Gauteng Province and increased over the 3 years. On pulsed-field gel electrophoresis analysis, serogroup A strains showed clonality, and serogroup B demonstrated considerable diversity. Selected isolates of serogroup A belonged to sequence type (ST)-1 (subgroup I/II) complex, serogroup B to ST-32/electrophoretic type (ET)-5 complex, and serogroup W135 to ST-11/ET-37 complex.
Despite progress in our understanding of the epidemiology of meningococcal disease, infection with Neisseria meningitidis continues to be a serious public health concern worldwide. Although occurring predominantly as sporadic disease with seasonal variation in most parts of the world, the highest burden of meningococcal disease occurs in the “meningitis belt” of sub-Saharan Africa, where epidemics are observed regularly (1). Historically these epidemics were associated with serogroup A and, to a lesser extent, serogroup C. However, serogroup W135 has recently emerged as a cause of epidemic disease in Africa (2,3), after outbreaks in 2000 and 2001 in Saudi Arabia during the annual Hajj pilgrimage to Mecca (4–6). Epidemics of meningococcal disease have occurred in Africa outside the meningitis belt (7,8).
Meningococcal disease associated with epidemics in Africa is generally caused by a limited number of genetically defined clonal groups (9,10). The 3 serogroup A pandemic waves reaching the African meningitis belt were caused by clones of subgroup III (11,12), and the recent outbreaks of W135 in West Africa were caused by strains belonging to the ET-37 complex (3,13).
In South Africa, meningococcal disease (a clinically reportable condition since 1920) is endemic, with seasonal increases during the winter months (14,15). Incidence rates, as determined by clinical notifications to the Department of Health, have been steadily decreasing from ≈5–10/100,000 (1945–1975) to <2/100,000 (1992–1997) (16–18). Upsurges of disease with a periodicity of several years have been noted (17). During the late 1970s, the epidemiology changed from a preponderance of disease due to serogroup A in young adult black men on the gold mines in the Southern Transvaal (now Gauteng) Province, to mostly serogroup B disease affecting young mixed-race infants in Western Cape Province (15,16). Serogroup B has caused peaks in disease rates in Western Cape in 1979 (9,19–21) and again in 1988. Although predominant in Western Cape, serogroup B also caused cases in Johannesburg, Gauteng, during 1980–1982, where >60% of meningococcal disease in children was due to serogroup B (22). Increases in serogroup A disease in Gauteng were described in the 1980s and 1996 (18,23,24).
To better understand the recent epidemiology of invasive meningococcal disease in South Africa, we analyzed cases reported to a national laboratory-based surveillance system for a 3-year period, from August 1999 through July 2002. Isolates available from cases reported during this period were characterized further.
National laboratory-based surveillance for invasive disease caused by N. meningitidis is performed by the Respiratory and Meningeal Pathogens Research Unit (RMPRU) at the National Institute for Communicable Diseases (a branch of the National Health Laboratory Service) in Johannesburg, South Africa. Cases were defined as isolation of N. meningitidis from normally sterile body fluid specimens (blood, cerebrospinal fluid [CSF], or both) from patients in August 1999 through July 2002. Isolates were submitted voluntarily to RMPRU by ≈100 laboratories nationally. Laboratories were encouraged to submit case reports of laboratory-confirmed disease even if viable isolates were no longer available for submission. (Some isolates lost viability during transport to the central laboratory.) Annual audits were performed to ascertain missed cases, and these were included on the database (but were without viable isolates for further testing at the central laboratory). These audits identified 118 cases not reported, to reach a final total of 557 cases from the provinces/laboratories audited, which suggests that ≈70%–80% of laboratory-confirmed cases were reported to the surveillance system.
Serogroup was determined for 615 isolates by using latex slide agglutination with monoclonal antiserum to capsular polysaccharides A, B, C, X, Y, Z, and W135 (Murex Biotech Limited, Dartford, England, United Kingdom). Strains that did not react with these antisera were sent to the World Health Organization Collaborating Center for Reference and Research on Meningococci, Oslo, Norway, for serogrouping.
Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed on 573 viable isolates of serogroup A, B, C, W135, and Y meningococci by using a method adapted from Popovic et al. (25). PFGE restriction profiles were analyzed with the GelCompar version 4.1 software (Applied Maths, Kortrijk, Belgium). Dendrograms were created by using the unweighted pair group method with arithmetic averages. Analysis of the banding patterns was performed with the Dice coefficient and a position tolerance of 1.5% for the band migration distance. A PFGE cluster was defined as >3 isolates sharing >80% similarity on the dendrogram (25,26).
Multi-Locus Sequence Typing (MLST)
Incidence rates were calculated on the basis of the number of cases reported during the 12-month periods from August 1 through July 31 of the following year, divided by mid-year population estimates for years 2000, 2001, and 2002, respectively, obtained from the South African Health Information Systems Programme. The χ2 test for linear trend using EpiInfo 6 (version 6.04d; Centers for Disease Control and Prevention, Atlanta, Georgia, USA) was used to assess statistical significance of the changes during the 3-year period.
Epidemiology of Laboratory-confirmed Meningococcal Disease
From August 1999 through July 2002, 854 cases of invasive meningococcal disease were reported; age was known for 756 (88%) patients. Most cases (645, 76%) were diagnosed from positive culture of CSF specimens (with or without positive cultures from blood specimens); the other 209 (24%) were positive on blood culture alone. The incidence rates of disease reported to the network increased from 0.52 per 100,000 persons in 1999–2000, to 0.62 in 2000–2001, and 0.77 in 2001–2002 (p<0.001). Western Cape Province was responsible for 37% of cases reported nationally, and Gauteng Province was responsible for 41% of cases reported nationally (Figure 1). In Western Cape Province, disease rates remained relatively stable; rates of reported disease were calculated as 2.87/100,000, 1.91/100,000, and 2.27/100,000 for each 12-month period, respectively (p = 0.068) (Figure 2). The incidence rates in Gauteng Province increased from 0.54/100,000 in the first year to 1.42/100,000 and 1.99/100,000 in the subsequent 2 years (p<0.001) (Figure 3). Seasonal variation was observed; the highest number of cases was reported in July to October (winter and spring) (data not shown). The highest age-specific incidence of meningococcal disease was seen in infants <1 year of age; the average incidence rate was 6.7/100,000. One hundred eighty-two (24%) of patients were infants <1 year of age, 116 (15%) were children 2–4 years of age, and 127 (17%) were young adults 15–24 years of age.
Of the 854 cases of laboratory-confirmed meningococcal disease reported to the surveillance network, 615 (72%) had viable isolates available for serogrouping; 453 (74%) of these were isolated from CSF and 162 (26%) from blood culture alone. Serogrouping of the viable meningococcal isolates showed the following: serogroup B, 251 isolates (41%); A, 142 (23%); Y, 130 (21%); C, 50 (8%); W135, 31 (5%); X, 8 (1%); Z, 2 (<1%); and 29E, 1 (<1%) (Table 1).
Seventy percent (175/251) of serogroup B disease was reported from Western Cape Province, where the number of cases decreased progressively from 81 in the first year (1999–2000) to 38 (in the third year, 2001–2002) (Table 1) and incidence decreased from 1.85/100,000 to 0.82, respectively (p<0.001) (Figure 2 ). Eighty-five percent (121/142) of serogroup A disease came from Gauteng Province, and the annual number of cases increased from 9 to 78 during the study period (Table 1). The incidence rate increased from 0.11/100,000 in the first year to 0.86 in the third year (p<0.001) (Figure 3). The proportion of disease caused by serogroups C, W135, and Y remained stable during the 3-year period (Table 1). Serogroup W135 was most prevalent in Gauteng Province (19 [61%] of the 31 cases occurred there), and serogroup C was most prevalent in Western Cape Province (28 [56%] of 50).
The age-specific proportion of disease in patients with known age varied for serogroups. The highest proportion of serogroup A (38 [33%] of 114) and C (10 [20%] of 50) disease occurred in the 15- to 24-year age group; the highest proportion of disease caused by serogroup B (70 [29%] of 238) and Y (42 [38%] of 112) was in infants <1 year of age. Serogroup W135 was found in equal proportion in the <1-year age group (6 [23%] of 26) and 15–24 age group (7 [27%] of 26). Incidence rates for the most common serogroups (A, B, and Y) for the last year of surveillance showed the highest rates of disease in children <1 year of age (Figure 4). Serogroup A had the lowest rates of disease for infants of the 3 serogroups and also had a second small peak for young adults. These trends were similar in the previous 2 years.
Of 615 N. meningitidis isolates serogrouped, 573 (93%) isolates were characterized by PFGE. Forty-six of these isolates were selected for MLST (Table 2).
PFGE analysis of 123 serogroup A isolates showed a highly clonal population structure with a large cluster (cluster A-1) representing 89% (109/123) (Figure 5, Table 2). The proportion of serogroup A meningococcal disease associated with strains of cluster A-1 increased from 38% (5/13) in 1999–2000 to 97% (70/72) in 2001–2002 (p<0.001). Most isolates from this cluster (101/109, 93%) originated from Gauteng Province and increased from 56% (5/9) in the first year, to 97% (30/31 and 66/68, respectively) in the second and third years (p<0.001). MLST analysis of 12 isolates from cluster A-1 showed identical allelic profiles belonging to sequence type (ST)-1, the prototype ST for the ST-1 (subgroup I/II) complex (Table 2). MLST analysis of 4 isolates outside of cluster A-1 yielded strains belonging to ST-7 (n = 2), ST-254 (n = 1), and ST-175 (n = 1 (Table 2).
In total, 242 serogroup B N. meningitidis isolates were analyzed by PFGE. Five distinct clusters were observed, with a predominant cluster (cluster B-1) consisting of 38% (91/242) of the isolates (Figure 6). The proportion of isolates within this cluster was 36%, 36%, and 43% for each 12-month period, respectively (p = 0.369). Eighty-two percent (75/91) of the isolates from this cluster were from the Western Cape, and the proportion of these strains in this province remained stable over time. Five isolates from this cluster were selected for MLST analysis. Four isolates were ST-33 (Table 2). One isolate had a novel allele at the fumC locus (28); a new ST (ST-4239, still part of ST-32 complex) was assigned to this isolate.
The second largest cluster (cluster B-2) comprised 12% (29/242) of the total number of isolates characterized. Three isolates belonged to ST-41/44 lineage III, 2 of which were ST-154. The third isolate had a novel allele at the abcZ locus and was assigned ST-4242.
Clusters B-3, B-4, and B-5 comprised 9.5% (23/242), 7% (17), and 6% (14) of all serogroup B isolates, respectively. The remaining isolates were clustered into small groups or were unrelated.
PFGE of the 49 serogroup C meningococcal isolates showed 3 main clusters (clusters C-1, C-2, and C-3) (Table 2). Cluster C-1 comprised 31% (15/49) of the total number of serogroup C isolates and showed no particular concentration by province. Two isolates from this cluster were ST-11 (Table 2).
Isolates belonging to clusters C-2 and C-3 each made up 18% (9/49) of the total number of isolates characterized (Table 2). Isolates from both clusters came exclusively from Western Cape (18/18 isolates). MLST of 2 strains from each cluster identified ST-865 in cluster C-2 (an ST not associated with any broader ST complex), and ST-33 in cluster C-3 (Table 2). The remaining isolates all showed unrelated PFGE patterns.
Of the 31 serogroup W135 meningococci isolates analyzed by PFGE, a distinct cluster (cluster W-1) of isolates comprising 23 (74%) of 31 isolates was found (Table 2). Seventeen (74%) of cluster W-1 isolates came from Gauteng Province. MLST analysis of 4 isolates from cluster W-1 (2 isolates from Gauteng and 1 each from Western Cape and KwaZulu Natal Provinces) showed they were ST-11, the founder sequence type of the ST-11/electrophoretic type (ET)-37 complex. Cluster W-2 comprised 3 isolates from 3 provinces, and MLST of 1 of the isolates showed that it belonged to ST-4241 (ST-22 complex). The remaining isolates were unrelated.
PFGE analysis of the 128 serogroup Y meningococcal isolates showed 2 clusters (clusters Y-1 and Y-2; Table 2). The predominant cluster (cluster Y-1) consisted of 92 (72%) isolates. Twenty-five (27%) isolates from cluster Y-1 came from Free State Province, 27 (29%) from Gauteng Province, and 15 (16%) from Western Cape Province. MLST of 6 isolates from this cluster showed that they were ST-175 (Table 2).
A second cluster, cluster Y-2, comprised 15% (19/128) of isolates (Table 2). Fifty-three percent (10/19) of these isolates were from Gauteng Province. MLST analysis of 3 isolates showed 2 STs, 1 identified as ST-23 (2 isolates), with the third possessing a novel allele at the abcZ locus (assigned new ST-4245). The remaining isolates (17/128, 13%) demonstrated groups of 2, 3, or 5 isolates; and 4 unrelated isolates. MLST analysis of 1 of these isolates showed that it belonged to ST-175.
The endemic nature and low incidence rates of meningococcal disease in the study period confirm an epidemiology related more closely to industrialized countries (29,30) than to countries of the African meningitis belt. Rates of national disease, as calculated by clinical notifications, ranged between 1 and 2/100,000 from 1992 to 1997 (18) and are similar to those calculated in our study. Although laboratory-based surveillance in South Africa clearly underestimates the impact of disease, audits indicate that more than two thirds of laboratory-confirmed disease were reported, and we believe our data are representative enough to reflect general trends of disease.
Overall, the age group at greatest risk for disease was children <1 year of age, although there were some differences by serogroup. Serogroup B has been previously described to occur predominantly in infants (15,22,30); serogroup A disease also causes disease in adults (15,22,24). Serogroup Y disease occurring in older patients has been documented (30), but this was not observed in our study.
The high proportion of laboratory-confirmed cases from Gauteng and Western Cape Provinces could reflect better reporting by laboratories in these areas. These 2 provinces also had the most clinical notifications, which would be less reliant on laboratory facilities, to the Department of Health since the 1970s (18). Other parts of South Africa were noted to have much lower rates of disease (15). Although access to medical care may influence rates by province, the fulminant and distinctive clinical manifestations of meningococcal disease allow for adequate clinical reporting from health facilities. True environmental, socioeconomic, or host-related factors may be resulting in higher disease rates in these provinces. Climate varies between areas in the country: Western Cape has a Mediterranean climate with wet winters and hot, dry summers; Gauteng lies on a plateau and has a temperate climate with summer rainfall; and KwaZulu Natal has a predominantly subtropical climate (31).
The incidence rate of reported meningococcal disease increased from 1999 to 2002, and serogroup A, most prevalent in Gauteng Province, was the only serogroup of viable isolates to increase significantly. Cyclical changes in meningococcal disease occurring every 8 to 10 years have been noted in this province (18). Case ascertainment of prospectively reported cases may have increased as the surveillance became more established and as audits highlighted nonreporting from certain laboratories that were subsequently included in the surveillance. Serogroup A meningococci are associated with most outbreaks throughout the African meningitis belt (1). No discrete outbreaks were identified associated with serogroup A disease during the study period; however, unrecognized clusters may have occurred.
The increase in the number of cases of serogroup A reported from Gauteng Province was associated specifically with strains belonging to a distinct cluster identified by PFGE. Selected isolates from this cluster were confirmed as belonging to ST-1 (subgroup I/II) complex. These strains have caused epidemics worldwide (11,32,33). In South Africa, subgroup I strains were first identified in 1968 (1 isolate) (11,32) and from 1976 through 1983 (41 isolates) (32). In 1996, 49.5% (55/111) of isolates analyzed from an outbreak in South Africa were identified as serogroup A belonging to subgroup I; 13.5% (15/111) belonged to subgroup III (34). MLST analysis of 1 of these subgroup III isolates showed it was ST-5 (data not shown). Recently, in the meningitis belt, ST-5 (predominant in 1988–2001) has been replaced by ST-7 in 2002, and no ST-1 strains were identified (35). In our study, 2 isolates analyzed by MLST were confirmed as ST-7, which suggests that the third pandemic wave from People’s Republic of China may have reached South Africa (12,35). The predominant serogroup A strain causing disease in South Africa, however, was not the same strain as that in the meningitis belt.
The high proportion of sporadic serogroup B disease in the Western Cape has been well described since the late 1970s (15,19,36). Serogroup B is rarely reported from other countries in Africa, and our data reflect an epidemiology for this serogroup more consistent with industrialized countries (9,37). The proportion of serogroup B meningococcal disease nationally decreased significantly, mostly due to a decrease in the number of viable serogroup B isolates identified from the Western Cape. This province had no change in total reported disease rates. By PFGE this serogroup showed substantial diversity, a characteristic typical of sporadic serogroup B disease worldwide (30,38) and previously documented in the Western Cape (39). Complexes ST-32/ET-5 and ST-41/44/lineage III have been associated with outbreaks worldwide (9,37). These strains have been causing disease in the Western Cape since the late 1970s (9,21,39).
Serogroup Y accounts for approximately one third of all invasive meningococcal disease in the United States (30), but it has been rare in the African meningitis belt (1,35). A serogroup Y isolate with ST-175 has been previously described from The Gambia in 1988 (www.pubmlst.org/neisseria), and recently ST-23 and ST-2880 have been identified in the meningitis belt (35). Our data thus represent the first evidence of a major role for serogroup Y disease in Africa.
Serogroup C disease associated with sporadic disease and occasional outbreaks occurs in both industrialized and developing nations (1,30). Complexes ST-11/ET-37 and ST-32/ET-5 are hypervirulent meningococci reported worldwide (9,37). In South Africa, a community-based outbreak caused by strains of the ST-11/ET-37 complex was observed in 2003 (40). ST-865 strains have been reported to cause disease in Taiwan, Spain, and the United States (www.pubmlst.org/neisseria), but these were associated with nongroupable and non–serogroup C isolates. To our knowledge, we document the first serogroup C strain of ST-865.
Serogroup W135, associated with little disease worldwide (1,13), represented a small proportion of disease in our surveillance. Complex ST-11/ET-37 was responsible for outbreaks in 2000 and 2001 associated with the annual Hajj pilgrimage (4,6,13) and for outbreaks in Burkina Faso in 2001 (2). PFGE comparison of isolates from a predominant cluster in South Africa with an isolate from the Hajj outbreak showed that they were related (data not shown). Strains of ET-37 had been in South Africa in 1986 and 1990 (13), and this clone may have been reintroduced during the Hajj outbreak.
In conclusion, we identified sporadic and seasonal meningococcal disease in South Africa during the study period, caused by an increasing number of cases due to a clone of serogroup A in Gauteng Province. Diverse strains of serogroup B were responsible for stable prevalence of disease in Western Cape Province. Nationally, 21% of meningococcal disease was due to serogroup Y. Continued surveillance will provide valuable information for the development of public health strategies to minimize the risk for outbreaks in South Africa and neighboring countries.
Mr Coulson worked for the National Institute for Communicable Diseases, Johannesburg, South Africa, at the time this article was prepared. Currently, he is in the doctoral program in infectious diseases at the University of Georgia, Athens, USA. His research activities focus on the role of genes on the pathogenicity island in Rhodococcus equi in terms of survival and persistence in host macrophages.
We thank all the clinicians and laboratory staff throughout the country who report cases and send isolates for national surveillance; the reviewers for their constructive criticism; and Stephanie Schrag and Leonard Mayer for kind assistance in finalizing the article.
This research was supported by grants from the Medical Research Council, the National Institute for Communicable Diseases, and the University of the Witwatersrand, South Africa.
- Greenwood B. Manson lecture. Meningococcal meningitis in Africa.Trans R Soc Trop Med Hyg. 1999;93:341–53.
- Taha MK, Parent Du Chatelet I, Schlumberger M, Sanou I, Djibo S, de Chabalier F, Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger.J Clin Microbiol. 2002;40:1083–4.
- Nicolas P, Djibo S, Moussa A, Tenebray B, Boisier P, Chanteau S. Molecular epidemiology of meningococci isolated in Niger in 2003 shows serogroup A sequence type (ST)-7 and serogroup W135 ST-11 or ST-2881 strains.J Clin Microbiol. 2005;43:1437–8.
- Popovic T, Sacchi CT, Reeves MW, Whitney AM, Mayer LW, Noble CA, Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex.Emerg Infect Dis. 2000;6:428–9.
- Taha MK, Achtman M, Alonso JM, Greenwood B, Ramsay M, Fox A, Serogroup W135 meningococcal disease in Hajj pilgrims.Lancet. 2000;356:2159.
- Hahne SJ, Gray SJ, Aguilera JF, Crowcroft NS, Nichols T, W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001.[PMID: 11867116]. Lancet. 2002;16:582–3.
- Cunin P, Fonkoua MC, Kollo B, Bedifeh BA, Bayanak P, Martin PM, Neisseria meningitidis outside meningitis belt in southwest Cameroon.Emerg Infect Dis. 2003;9:1351–3.
- World Health Organization. Epidemic and pandemic alert and response (EPR): disease outbreak news [cited 2006 Mar 24]. Available from http://www.who.int/csr/don/2002_09_12a/en/index.html
- Caugant DA, Froholm LO, Bovre K, Holten E, Frasch CE, Mocca LF, Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease.Proc Natl Acad Sci U S A. 1986;83:4927–31.
- Achtman M. Epidemic spread and antigenic variability of Neisseria meningitidis.Trends Microbiol. 1995;3:186–92.
- Wang JF, Caugant DA, Li X, Hu X, Poolman JT, Crowe BA, Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People’s Republic of China.Infect Immun. 1992;60:5267–82.
- Nicolas P, Decousset L, Riglet V, Castelli P, Stor R, Blanchet G. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa.Emerg Infect Dis. 2001;7:849–54.
- Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex.J Infect Dis. 2002;185:1596–605.
- Ordman D. The epidemiology of meningitis in South Africa.S Afr Med J. 1932;6:757–65.
- Küstner H. Meningococcal infection – changing epidemiological patterns in South Africa. Epidemiological Comments. 1979;Aug:1–15.
- Whitehorn R. Meningococcal infection: the current epidemiological pattern in South Africa.Epidemiological Comments.1985;12:2–14.
- Küstner H. Meningococcal infection.Epidemiological Comments.1988;15:17–33.
- Bikitsha N. Meningococcal meningitis in South Africa.Epidemiological Comments.1998;24:2–9.
- Donald PR, Burger PJ, van Zyl LE. Meningococcal disease at Tygerberg Hospital.S Afr Med J. 1981;60:271–5.
- Ryder CS, Beatty DW, Heese HD. Group B meningococcal infection in children during an epidemic in Cape Town, South Africa.Ann Trop Paediatr. 1987;7:47–53.
- Caugant DA, Zollinger WD, Mocca LF, Frasch CE, Whittam TS, Froholm LO, Genetic relationships and clonal population structure of serotype 2 strains of Neisseria meningitidis.Infect Immun. 1987;55:1503–12.
- Liebowitz LD, Koornhof HJ, Barrett M, Bracken C, Davis A, Fraser N, Bacterial meningitis in Johannesburg—1980–1982.S Afr Med J. 1984;66:677–9.
- Balfour TM, Edginton ME, Koornhof H, McGee L, Floyd L. An outbreak of meningococcal meningitis in Gauteng, spring 1996.S Afr Med J. 1999;89:411–5.
- Sonnenberg P, Silber E, Ho KC, Koornhof HJ. Meningococcal disease in South African goldmines–epidemiology and strategies for control.S Afr Med J. 2000;90:513–7.
- Popovic T, Schmink S, Rosenstein NA, Ajello GW, Reeves MW, Plikaytis B, Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C.J Clin Microbiol. 2001;39:75–85.
- Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.J Clin Microbiol. 1995;33:2233–9.
- Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.Proc Natl Acad Sci U S A. 1998;95:3140–5.
- Jolley KA, Chan MS, Maiden MC. mlstdbNet-distributed multi-locus sequence typing (MLST) databases.BMC Bioinformatics. 2004;5:86.
- Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993–6. European Meningitis Surveillance Group.Epidemiol Infect. 1999;122:41–9.
- Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, The changing epidemiology of meningococcal disease in the United States, 1992–1996.J Infect Dis. 1999;180:1894–901.
- Winter K, Oelofse C, Bottaro J. Oxford senior atlas for Southern Africa. 1st edition. Cape Town: Oxford University Press Southern Africa; 2001.
- Olyhoek T, Crowe BA, Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983.Rev Infect Dis. 1987;9:665–92.
- Achtman M, Kusecek B, Morelli G, Eickmann K, Wang JF, Crowe B, A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A.J Infect Dis. 1992;165:53–68.
- McGee L, Koornhof HJ, Caugant DA. Epidemic spread of subgroup III of Neisseria meningitidis serogroup A to South Africa in 1996.Clin Infect Dis. 1998;27:1214–20.
- Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes.J Clin Microbiol. 2005;43:5129–35.
- Potter PC, Donald PR, Moodie J, Slater C, Kibel MA. Meningitis in Cape Town children.S Afr Med J. 1984;66:759–62.
- Wenger JD. Serogroup B meningococcal disease: new outbreaks, new strategies.JAMA. 1999;281:1541–3.
- Caugant DA, Mocca LF, Frasch CE, Froholm LO, Zollinger WD, Selander RK. Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern.J Bacteriol. 1987;169:2781–92.
- Orren A, Caugant DA, Fijen CA, Dankert J, van Schalkwyk EJ, Poolman JT, Characterization of strains of Neisseria meningitidis recovered from complement-sufficient and complement-deficient patients in the Western Cape Province, South Africa.J Clin Microbiol. 1994;32:2185–91.
- Coulson C, von Gottberg A, Smith A, Klugman K. Meningococcal outbreak 2003: investigation of a community-based outbreak of serogroup C Neisseria meningitidis in South Africa.Communicable Diseases Surveillance Bulletin.2003;1:13–6.
Suggested citation for this article: Coulson GB, von Gottberg A, du Plessis M, Smith AM, de Gouveia L, Klugman KP, et al. Meningococcal disease in South Africa, 1999–2002. Emerg Infect Dis [serial on the Internet]. 2007 Feb [date cited]. Available from http://wwwnc.cdc.gov/eid/article/13/2/05-1553
1GERMS-SA: Sandeep Vasaikar (Eastern Cape); Nolan Janse van Rensberg, Peter Smith (Free State); Khatija Ahmed, Heather Crewe-Brown, Mike Dove, Charles Feldman, Alan Karstaedt, Olga Perovic, Pyu-Pyu Sein, Ruth Lekalakala (Gauteng); Wim Sturm (KwaZulu Natal); Ken Hamese (Limpopo); Keith Bauer (Mpumalanga); Denise Roditi, Rena Hoffmann, Lynne Liebowitz, John Simpson, Andrew Whitelaw (Western Cape); Adrian Brink (AMPATH); Claire Heney (Lancet); Martinus Senekal (PathCare).
- Page created: June 29, 2010
- Page last updated: June 29, 2010
- Page last reviewed: June 29, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)